GlobeNewswire by notified

PRFoods Audited Consolidated Annual Report 2020/2021

Share

Management Commentary

The most difficult year in group history is over. We were attacked from three fronts: from one side the corona crisis caused a situation, where demand for fish products and raw material prices were dropping drastically. This led to decrease in gross margin and revenue. Secondly, we were entering into the crisis with high financial leverage due to recent acquisitions of companies and banks demanded aggressively us to reduce loan portfolio. Third, group previous management of Finland was not able and didn’t want to react to changes, which meant that problems were accumulating in that unit. Dealing with all three crisis at the same time was increasing group loss – we were forced to make decisions, which would not normally have been done.

As a result of above, group’s turnover decreased yearly bases 25% to 58.7 million euros(2019/2020: 78.3 million euros).

EBITDA loss 1.3 million euros was the final result – historically first one for us (2019/2020: EBITDA profit 1.9 million euros). Net loss 5.2 million euros (2019/2020: net loss 1.9 million euros).

EBITDA was significantly impacted: raw material prices increased abruptly when corona restrictions were loosened, but at the same time Finnish market sales prices were agreed during winter, when prices were lower. This led to the situation in last quarter, where we were forced to sell some products below COGS. To end this we had to release the local CEO and informed customers about ending non-profitable contracts.

From positive side the group’s cash flow from operations was positive by 2 million euros and total cashflow over the period improved by 0.53 million euros. We also reduced our net debt and reduced significantly short term liabilities of the company. Our fish farming unit presented better results and was a backbone of the Scandinavian business. In that field we miss permission from Estonian government to begin with large-scale fish-farming – due to that we missed significant revenue.

Although our Scotland units net profit and turnover decreased up to 30%, John Ross Jr managed to end the year with 1.4 million euros EBITDA. This was outstanding as well as Estonian unit, who managed to rise from month to month retail product sales despite HoReCa markets decrease close to zero.

The number of employees decreased by ca 10% on annual basis. Finland’s units cost decrease didn’t match the decrease of revenue and margins. In conclusion we can say that Finnish unit was the root cause of problems.

PRFoodsi action plan to overcome the crisis is: 

  1. Decrease overall debt level through positiive EBITDA and strengthening of equity base.
  2. Completely restructure Finnish division, either through disposal or closure of loss-making business units. Eliminate totally all low margin products form Finnish sales.
  3. Increase reeteil sales in UK, EU markets, including home market Estonia.
  4. Group’strategic focus is on fish farming, as a division that has been profitable every year. Target is to reach by 2023 fish farming volume of 10,000 tons, giving additional 45-50 million euros in sales by year.

Group’s financial position is not simple. At the same time, we must remember that 11 million euros bonds have been issued solely for refinancing of John Ross Jr. acquisition and John Ross Jr results have not been impacted so severly, their operational cash flow is strong and they pay regularly dividends to parent company, therefore we find their leverage to be acceptable. Fish farming requires long term capital for fish feed and this is in process.

Last year we were forced to reduce significantly working capital financing through banks, which put strain on company’s finances. We have reduced significantly working capital needs in operations, also through lower inventory. Most important is to restore profitability in the environment of lower sales and restructure loss-making business units.

Having hardened for second year in corona crisis, we know that it is not sustainable to rely on outside help and all difficult decisions need to be taken sooner than later. For our advantage the fish market has started much stronger this year and is more predictable, the demand for our products is growing. The only objective of new financial year is profit and everything that blocks our road to profitabilty must be eliminated.

Key Ratios of the GrouP

INCOME STATEMENT
mln EUR
2020/20212019/20202018/ 20192017/20182016/2017
Sales58.778.385.794.951.1
Gross profit5.09.611.913.23.9
EBITDA from operations*-1.22.84.06.00.6
EBITDA-1.31.91.74.42.0
EBIT-3.9-0.7-0.52.30.7
EBT-5.0-1.8-1.21.40.5
Net profit (-loss) -5.2-1.9-1.51.00.2
Gross margin 8.5%12.2%13.9%13.9%7.7%
Operational EBITDA margin-2.1%3.5%4.7%6.3%1.2%
EBITDA margin-2.1%2.4%2.0%4.7%3.8%
EBIT margin-6.6%-0.9%-0.5%2.5%1.4%
EBT margin-8.5%-2.2%-1.4%1.5%1.1%
Net margin -8.8%-2.4%-1.7%1.1%0.4%
Operating expense ratio16.1%13.4%12.5%10.5%9.6%
BALANCE SHEET
mln EUR
30.06.202130.06.202030.06.201930.06.201830.06.2017
Net debt22.420.720.518.11.0
Equity15.819.821.923.322.7
Working capital-3.2-4.0-3.12.811.5
Assets55.657.162.565.533.5
Liquidity ratio0.8x0.8x0.9x1.1x2.3x
Equity ratio 28.4%34.7%35.0%35.6%67.8%
Gearing ratio58.7%51.1%48.3%43.7%4.1%
Debt to Asset0.7x0.7x0.7x0.6x0.3x
Net debt-to-EBITDA from operations-17.9x7.5x5.1x3.0x1.6x
ROE-29.0%-9.1%-6.5%4.3%0.9%
ROA-9.2%-3.2%-2.3%2.0%0.6%

* before one-offs and fair value adjustment of fish stock

Indrek Kasela
AS PRFoods
Member of the Management Board
Phone: +372 452 1470
investor@prfoods.ee
www.prfoods.ee



Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date25.4.2024 07:30:00 CEST | Press release

Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital Announced positive top-line results from Up-LIFT pivotal study Forged partnership to provide rapid access to US Veterans Health Administration Continued to pioneer brain-computer interface therapies for SCI EINDHOVEN, The Netherlands, April 25, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its Full Year 2023 Financial and Operating Results. “In 2023, we made substantial progress against our objectives and laid the foundation to bring our ARC-EX System to the US market later this year,” said Dave Marver, CEO of ONWARD Medical. “We are off to a strong start again in 2024, raising EUR 20M in equity capital and submitting our De Novo application to the FDA for the ARC-EX System.” Full Year 2

Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance25.4.2024 07:30:00 CEST | Press release

Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performanceR&D expenses grew 11.8%, reflecting strategic shift of resources into developmentSG&A expenses grew 2.9%, less than sales growthBusiness EPS(1) of €1.78, down 17.6% reported and 7.4% at CERIFRS EPS of €0.91, down 43.1% reported R&D transformation advanced further Three regulatory approvals: new Dupixent indications in the US and Japan and Beyfortus in JapanPositive phase 3 results for rilzabrutinib in immune thrombocytopenia, a rare diseaseReaffirming increasing pipeline news flow over 2024-2

Huhtamäki Oyj’s Interim Report January 1–March 31, 2024: Improved operational profitability25.4.2024 07:30:00 CEST | Press release

HUHTAMÄKI OYJ INTERIM REPORT 25.4.2024 AT 8:30 EEST Q1 2024 in brief Net sales decreased 4% to EUR 1,004 million (EUR 1,047 million)Comparable net sales growth was -2% at Group levelReported EBIT was EUR 78 million (EUR 87 million); adjusted EBIT was EUR 99 million (EUR 92 million)Reported EPS was EUR 0.35 (EUR 0.47); adjusted EPS was EUR 0.55 (EUR 0.51)The impact of currency movements was EUR -17 million on the Group's net sales and EUR -2 million on EBIT Key figures EUR million Q1 2024 Q1 2023 Change 2023 Net sales 1,003.9 1,047.1 -4% 4,168.9 Comparable net sales growth -2% 2% -2% Adjusted EBITDA1 149.0 140.5 6% 590.1 Margin1 14.8% 13.4% 14.2% EBITDA 137.7 138.1 -0% 621.2 Adjusted EBIT2 98.8 92.1 7% 392.6 Margin2 9.8% 8.8% 9.4% EBIT 77.6 87.4 -11% 380.9 Adjusted EPS, EUR3 0.55 0.51 7% 2.32 EPS, EUR 0.35 0.47 -27% 1.97 Adjusted ROI2 11.5% 10.7% 11.2% Adjusted ROE3 13.3% 13.7% 13.2% ROI 10.7% 11.0% 10.9% ROE 11.0% 14.3% 11.8% Capital expenditure 36.6 65.2 -44% 318.7 Free Cash Flow 38.2

TRAINERS’ HOUSE GROUP INTERIM REPORT 1 JANUARY – 31 MARCH 202425.4.2024 07:30:00 CEST | Press release

TRAINERS' HOUSE GROUP, STOCK EXCHANGE RELEASE, 25 APRIL 2024 at 8:30 January-March 2024 in brief net sales EUR 2.3 million (EUR 2.8 million), change of -18.3 % compared to the corresponding period of the previous yearoperating result EUR 0.2 million (EUR 0.4 million), 7.3 % of net sales (14.5 %)cash flow from operations EUR 0.2 million (EUR 0.3 million)earnings per share EUR 0.08 (EUR 0.19) Key figures at the end of first quarter of 2024 cash and cash equivalents EUR 1.3 million (EUR 2.5 million)interest-bearing liabilities of EUR 0.8 million (EUR 0.4 million) and interest-bearing net debt of EUR -0.5 million (EUR -2.1 million).equity ratio 64.3 % (59.5 %) OUTLOOK FOR 2024 The company estimates the operating profit for 2024 to be negative. CEO ARTO HEIMONEN In the review period, acquiring new orders was challenging. The demand for services connected to overall well-being, mental growth and creating of meanings is growing. The sales of the company's personal training products strengthen

Flow Traders Q1 2024 Trading Update25.4.2024 07:30:00 CEST | Press release

Flow Traders Q1 2024 Trading Update Amsterdam, the Netherlands - Flow Traders Ltd. (Euronext: FLOW) announces its unaudited Q1 2024 trading update. Highlights Flow Traders recorded Net Trading Income of €127.1m and Total Income of €129.6m in Q124, compared to €72.7m and €74.3m, respectively, in Q423, and €110.5m for both in Q123. Flow Traders’ Value Traded increased 7% in Q124 when compared to last quarter and was flat when compared to the same period last year.Total Operating Expenses were €68.5m in Q124, compared to €62.5m in Q423 and €70.3m in Q123, with Fixed Operating Expenses of €43.6m, compared to €40.4m in Q423 and €43.9m in Q123.EBITDA was €61.1m in Q124, generating an EBITDA margin of 47%, compared to €11.8m and 16% in Q423 and €40.2m and 36% in Q123. Net Profit was €45.9m in Q124, yielding a basic EPS of €1.06, compared to €6.4m of Net Profit and €0.15 of basic EPS in Q423 and €27.7m and €0.64 in Q123. Trading capital stood at €609m at the end of Q124 and generated a 52% ret

HiddenA line styled icon from Orion Icon Library.Eye